NewsMV

Glucotrack settles Apimeds debt dispute for up to $4.125 million, issues convertible note at $2.98 per share

9/10/2026

In focus for $GCTK: a September 4 settlement that places Glucotrack, Inc.

jointly and severally on the hook for up to $4.125 million to resolve a debt Alto Opportunity Master Fund, SPC had asserted against Apimeds Pharmaceuticals US, Inc.

at approximately $10.9 million in outstanding principal. The first quarterly installment on the settlement's convertible note, $500,000 in principal, comes due November 30.

The settling parties include Glucotrack, Chief Executive Officer Erik Emerson, RXRR Capital Partners LLC, and Lōkahi Therapeutics, Inc.